News
-
11 November 2019
New Data Uncover Deeper Insight into Tebentafusp (IMCgp100) Clinical Activity in Patients with Advanced Melanoma, Including Uveal -
31 October 2019
Immunocore to Spotlight ImmTAC® Platform Research at 2019 SITC Annual Conference -
18 July 2019
Immunocore and Pulse Infoframe, Inc. Partner with Leading Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma -
16 July 2019
Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers -
3 June 2019
New Biomarker Research Builds Further Understanding of Tebentafusp (IMCgp100) Mechanism of Action, Link to Clinical Activity in Advanced Melanoma -
30 May 2019
Immunocore to present at the Jefferies 2019 Global Healthcare Conference in New York -
16 May 2019
Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting -
13 May 2019
Immunocore Launches Campaign to Educate Physicians on Rare Eye Cancer -
7 May 2019
Immunocore appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer -
3 April 2019
Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma